Cargando…

Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic Programs

BACKGROUND: Overall survival advantage of chemotherapy before versus after metastasectomy of liver or lung lesion is not clear for colon cancer with synchronous liver or lung metastasis. MATERIALS AND METHODS: Adults 20 years or older with primary colon cancer and single organ metastatic disease eit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hao, Zhonglin, Parasramka, Saurabh, Chen, Quan, Jacob, Aasems, Huang, Bin, Mullett, Timothy, Benson, Al B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Gastrointestinal Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847538/ https://www.ncbi.nlm.nih.gov/pubmed/36200844 http://dx.doi.org/10.1093/oncolo/oyac209

Ejemplares similares

In Reply: Overall Survival of Resectable Metastatic Colon Cancer Treated With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy in Non-academic Program
por: Hao, Zhonglin, et al.
Publicado: (2023)

Regarding “Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic Programs”
por: Su, I-Hsuan, et al.
Publicado: (2023)

Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer
por: Khalil, Lana, et al.
Publicado: (2022)

Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)
por: Singh, Preet Paul, et al.
Publicado: (2016)

Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer
por: Kim, Jin K, et al.
Publicado: (2022)

Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
por: He, Wenwu, et al.
Publicado: (2022)

Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers
por: David, John M., et al.
Publicado: (2018)

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study
por: Moriwaki, Toshikazu, et al.
Publicado: (2017)

Immunohistochemistry‐Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer
por: Li, Yaqi, et al.
Publicado: (2020)

Safety and Feasibility of Additional Tumor Debulking to First‐Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer
por: Gootjes, Elske C., et al.
Publicado: (2020)

A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803
por: Niedzwiecki, Donna, et al.
Publicado: (2016)

Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma
por: Canton, Clémence, et al.
Publicado: (2022)

Initial Results of a Prospective Study of Adjuvant Pancreatic Stereotactic Body Radiation Therapy for Close or Positive Margins
por: Bernard, Mark E., et al.
Publicado: (2018)

Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance)
por: Lee, Seohyuk, et al.
Publicado: (2022)

Phase 1 Study of Neoadjuvant Short-Course Radiation Therapy Concurrent With Infusional 5-Fluorouracil for the Treatment of Locally Advanced Rectal Cancer
por: Fields, Emma C., et al.
Publicado: (2019)

Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers
por: Schunke, Kathryn J., et al.
Publicado: (2017)

Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors
por: Joseph, Cissimol P., et al.
Publicado: (2021)

A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer
por: Chen, Kuei-Ting, et al.
Publicado: (2023)

The Role of Systemic Therapy in Resectable Colorectal Liver Metastases: Systematic Review and Network Meta-Analysis
por: Sonbol, Mohamad Bassam, et al.
Publicado: (2022)

Real‐World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
por: Patel, Anuj K., et al.
Publicado: (2019)

Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States
por: Paluri, Ravi, et al.
Publicado: (2022)

The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer
por: Fernández Montes, Ana, et al.
Publicado: (2023)

Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer
por: Perez, Kimberly, et al.
Publicado: (2023)

Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma
por: Moore, Jonathan L., et al.
Publicado: (2023)

Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Zhuang, Tony Z, et al.
Publicado: (2022)

Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study
por: Zhou, Yongjian, et al.
Publicado: (2023)

Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy
por: Cheng, Zhi, et al.
Publicado: (2018)

Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
por: Fujii, Hironori, et al.
Publicado: (2019)

Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial
por: Lipsyc-Sharf, Marla, et al.
Publicado: (2022)

Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss
por: Best, Till Dominik, et al.
Publicado: (2021)

Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2‐Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
por: Al‐Batran, Salah‐Eddin, et al.
Publicado: (2020)

Perioperative Chemotherapy Could Not Improve the Prognosis of Gastric Cancer Patients With Mismatch Repair Deficiency: A Multicenter, Real-World Study
por: Zhao, Lulu, et al.
Publicado: (2023)

Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study
por: Fucà, Giovanni, et al.
Publicado: (2022)

Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis
por: Parikh, Aparna R, et al.
Publicado: (2022)

Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer
por: Wang, Chongkai, et al.
Publicado: (2022)

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer
por: Sobrero, Alberto, et al.
Publicado: (2020)

Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes
por: Bekaii-Saab, Tanios S, et al.
Publicado: (2023)

Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience
por: Serpas Higbie, Victoria, et al.
Publicado: (2022)

Placenta-specific protein 1 enhances liver metastatic potential and is associated with the PI3K/AKT/NF-κB signaling pathway in colorectal cancer
por: Ma, Jiachi, et al.
Publicado: (2020)

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer
por: Fakih, Marwan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qin0v3jd5qjoqevab8t2mt93ch